Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype

International Journal of Cancer

Volumn 122, Issue 2, 2008, Pages 281-288

  Solar, Peter ^a,b   Feldman, Laurie ^a   Jeong, Jee Yeong ^a   Busingye, Jacqueline R ^a   Sytkowski, Arthur J ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Chemoresistance; Erythropoietin; Ovarian cancer; Paclitaxel; Signaling

Indexed keywords

CARBOPLATIN; CISPLATIN; ERYTHROPOIETIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PROTEIN BCL 10; PROTEIN BCL 2; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONCENTRATION (PARAMETERS); DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOSOME; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 36849026097     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23071     Document Type: Article

References (64)

1. Sytkowski AJ. Erythropoietin: blood, brain and beyond. Weinheim: Wiley-VCH, 2004.
2. Brower V. Normal and neoplastic prostate cells have Epo receptors. Lancet Oncol 2003;4:69.
3. Brower V. Erythropoietin may impair, not improve, cancer survival. Nat Med 2003;9:1439.
4. Brower V. Epoetin for cancer patients: a boon or a danger? J Natl Cancer Inst 2003;95:1820-1.
5. Henke M, Laszig R, Rube C, Schafer U, Haase K-D, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
6. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
7. Overgaard J. Interim analysis of DAHANCA 10: study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck. Danish Head and Neck Cancer Group. 2006.
8. Goldberg P. Danish researchers post long-awaited Aranesp results - ever so discreetly. Cancer Lett 2007;33:1-6.
9. Showers MO, Moreau JF, Linnekin D, Druker B, D'Andrea AD. Activation of the erythropoietin receptor by the friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation. Blood 1992;80:3070-8.
10. Wilson JK, Sargent JM, Elgie AW, Hill JG, Taylor CG. A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br J Cancer 1990;62:189-94.
11. Fanning J, Biddle WC, Goldrosen M, Crickard K, Crickard U, Piver MS, Foon KA. Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay. Gynecol Oncol 1990;39:119-22.
12. Huxham IM, Barlow AL, Lewis AD, Plumb J, Mairs RJ, Gaze MN, Workman P. Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780ad) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis. Int J Cancer 1994;59:94-102.
13. Spinner DM, Brandstetter T, Kiechle-Schwarz M, Du Bois A, Angel P, Bauknecht T. C-jun expression and growth stimulation in human ovarian carcinoma cell lines following exposure to cytokines. Int J Cancer 1995;63:423-7.
14. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt M-AV, Bast RC, Jr, Mills GB. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 1999;5:3704-10.
15. Yoshida H, Cheng W, Hung J, Montell D, Geisbrecht E, Rosen D, Liu J, Naora H. Lessons from border cell migration in the drosophila ovary: a role for myosin vi in dissemination of human ovarian cancer. Proc Natl Acad Sci USA 2004;101:8144-9.
16. Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW, Koeffler HP. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 2005;11:7243-54.
17. Muthukumaran N, Miletti-Gonzalez KE, Ravindranath AK, Rodriguez-Rodriguez L. Tumor necrosis factor-α differentially modulates CD44 expression in ovarian cancer cells. Mol Cancer Res 2006;4: 511-20.
18. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. Bax enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 1996;93:14094-9.
19. Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak up-regulation and the functional status of p53. Mol Pharmacol 1998;53:819-26.
20. Samanta AK, Huang HJ, Bast RC, Jr, Liao WS-L. Overexpression of Mekk3 confers resistance to apoptosis through activation of NFκB. J Biol Chem 2004;279:7576-83.
21. Sugimura M, Sagae S, Ishioka S, Nishioka Y, Tsukada K, Kudo R. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone. Oncology 2004;66:53-61.
22. Williams J, Lucas P, Griffith K, Choi M, Fogoros S, Hu Y, Liu J. Expression of Bcl-x(L) in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005;96:287-95.
23. Eva A, Robbins KC, Andersen PR, Srinivasan A, Tronick SR, Reddy EP, Ellmore NW, Galen AT, Lautenberger JA, Papas TS, Westin EH, Wong-Staal F, et al. Cellular genes analogous to retroviral one genes are transcribed in human tumour cells. Nature 1982;295:116-19.
24. Louie KG, Hamilton TC, Winker MA, Behrens BC, Tsuruo T, Klecker RW, McKoy WM, Grotzinger KR, Myers CE, Young RC. Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochem Pharmacol 1986;35:467-72.
25. Perez RP, Handel LM, Hamilton TC. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor. Gynecol Oncol 1992;46:82-7.
26. Pan B, Yao KS, Monia BP, Dean NM, McKay RA, Hamilton TC, O'Dwyer PJ. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (Isis 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem Pharmacol 2002;63:1699-707.
27. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003;63: 1311-16.
28. Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, Weiss MJ. Gata-1 and erythropoietin cooperate to promote erythroid cell survival by regulating Bcl-xL expression. Blood 1999;94:87-96.
29. Jacobs-Helber SM, Wickrema A, Birrer MJ, Sawyer ST. AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells. Mol Cell Biol 1998;18:3699-707.
30. Tsushima H, Urata Y, Miyazaki Y, Fuchigami K, Kuriyama K, Kondo T, Tomonaga M. Human erythropoietin receptor increases GATA-2 and Bcl-xL by a protein kinase c-dependent pathway in human erythropoietin-dependent cell line AS-E2. Cell Growth Differ 1997;8: 1317-28.
31. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, Fernandez-Luna JL. Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999;274:22165-9.
32. Sawyer ST, Jacobs-Helber SM. Unraveling distinct intracellular signals that promote survival and proliferation: study of erythropoietin, stem cell factor, and constitutive signaling in leukemic cells. J Hematother Stem Cell Res 2000;9:21-9.
33. Dolznig H, Habermann B, Stangl K, Deiner EM, Moriggl R, Beug H, Mullner EW. Apoptosis protection by the Epo target Bcl-xL1 allows factor-independent differentiation of primary erythroblasts. Curr Biol 2002;12:1076-85.
34. Hafid-Medheb K, Augery-Bourget Y, Minatchy M-N, Hanania N, Robert-Lezenes J. Bcl-xL is required for heme synthesis during the chemical induction of erythroid differentiation of murine erythroleukemia cells independently of its antiapoptotic function. Blood 2003;101:2575-83.
35. Rhodes MM, Kopsombut P, Bondurant MC, Price JO, Koury MJ. Bcl-xL prevents apoptosis of late-stage erythroblasts but does not mediate the antiapoptotic effect of erythropoietin. Blood 2005;106:1857-63.
36. Chen C, Sytkowski AJ. Erythropoietin activates two distinct signaling pathways required for the initiation and the elongation of c-myc. J Biol Chem 2001;276:38518-26.
37. Chen C, Sytkowski AJ. Erythropoietin regulation of Raf-1 and Mek: evidence for a Ras-independent mechanism. Blood 2004;104: 73-80.
38. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94.
39. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-9.
40. Pang L, Sawada T, Decker SJ, Saltiel AR. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 1995;270:13585-8.
41. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. Mek/Erk signaling pathway regulates the expression of Bcl-2, Bcl-x(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000;79:355-69.
42. McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990;76:1718-22.
43. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung M-C. E1a-mediated paclitaxel sensitization in Her-2/Neu-overexpressing ovarian cancer SKOV3.Ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000;6:250-9.
44. Wang T-H, Popp DM, Wang H-S, Saitoh M, Mural JG, Henley DC, Ichijo H, Wimalasena J. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem 1999;274:8208-16.
45. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999;59: 3077-83.
46. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001;61:1862-8.
47. Yang X, Fraser M, Moll UM, Basak A, Tsang BK. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 2006;66: 3126-36.
48. Silver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999;73:280-4.
49. Belenkov AI, Shenouda G, Rizhevskaya E, Coumoyer D, Belzile J-P, Souhami L, Devic S, Chow TYK. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 2004;3:1525-32.
50. Thome M, Tschopp J. Bcl10. Curr Biol 2002;12:R45.
51. Lin X, Wang D. The roles of Carma1, Bcl10, and Malt1 in antigen receptor signaling. Semin Immunol 2004;16:429-35.
52. Fischer KD, Tedford K, Wirth T. New roles for Bcl10 in B-cell development and LPS response. Trends Immunol 2004;25:113-16.
53. Reed JC. Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol Lett 1995;82:155-8.
54. Korsmeyer SJ. Bcl-2 gene family and the regulation of programmed cell death. Cancer Res 1999;59 (7 Suppl):1693s-700s.
55. Haughn L, Hawley RG, Morrison DK, von Boehmer H, Hockenbery DM. Bcl-2 and Bcl-xl restrict lineage choice during hematopoietic differentiation. J Biol Chem 2003;278:25158-65.
56. Nakamura H, Kumei Y, Morita S, Shimokawa H, Ohya K, Shinomiya K. Antagonism between apoptotic (bax/bcl-2) and antiapoptotic (iap) signals in human osteoblastic cells under vector-averaged gravity condition. Ann N Y Acad Sci 2003;1010:143-7.
57. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO, Scambia G. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 2003;64:51-8.
58. Andre N, Braguer D, Brasseur G, Goncalves A, Lemesle-Meunier D, Guise S, Jordan MA, Briand C. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res 2000;60:5349-53.
59. Yamasaki M, Mishima HK, Yamashita H, Kashiwagi K, Murata K, Minamoto A, Inaba T. Neuroprotective effects of erythropoietin on glutamate and nitric oxide toxicity in primary cultured retinal ganglion cells. Brain Res 2005;1050:15-26.
60. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-xL and Bcl-2. Blood 1996;88: 1576-82.
61. Emir M, Ozisik K, Cagli K, Misirlioglu M, Ozisik P, Iscan Z, Yildirim E, Kilinc K, Sener E. Effect of erythropoietin on Bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury. Transplant Proc 2004;36:2935-8.
62. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJ, Reed NS, Fairlamb DJ, Chan SY, Godfrey KA, Kristensen GB, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy.[comment]. Med Oncol 1998;15:174-82.
63. Markman M. The prophylactic administration of recombinant erythropoietin in the management of ovarian cancer: time for a definitive phase 3 randomized trial. Gynecol Oncol 2002;86:237-8.
64. Hudis CA, Van Belle S. Introduction: examining the potential impact of anemia treatment on clinical outcomes in anemic cancer patients. Oncologist 2004;9(Suppl 5):1-3.